AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19155592
Drug: 75 g
RxNorm normalized name: Zosyn 3.375 GM Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 g maltodextrin + 7.5 g D-psicose
Trial: 16753648
Drug: Not in
RxNorm normalized name: Blood group antigen associated with but not included in MNS system
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not in treatment (NT)
Trial: 10506661
Drug: Experimentally raised
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimentally raised anti-osteopontin antibodies
Trial: 8932874
Drug: ICI182780 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI182780 6 mg/day (n = 10) for 7 days
Trial: 8932874
Drug: Tamoxifen (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (4 x 40 mg on day 1, 20 mg/day thereafter, median 21 days) (n = 8)
Trial: 8932874
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no preoperative treatment n = 9, placebo n = 7)
Trial: 1411629
Drug: Carboplatin 50
RxNorm normalized name: CARBOPLATIN 50MG/VIL INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin 50 mg/m2 with 67.2 Gy radiation
Trial: 1992531
Drug: Carboplatin (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin (various doses) with 58.8 Gy radiation
Trial: 1992531
Drug: Carboplatin (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin (various doses) with radiation
Trial: 20838741
Drug: Enoxaparin 40
RxNorm normalized name: ENOXAPARIN 40MG/0.4ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 40 mg once daily in ambulatory patients
Trial: 20838741
Drug: Enoxaparin 40
RxNorm normalized name: ENOXAPARIN 40MG/0.4ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 40 mg once daily in non-ambulatory patients
Trial: 18269820
Drug: Primary PCI
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary PCI combined with tirofiban therapy (Tirofiban group, n = 80)
Trial: 15386821
Drug: Metformin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin plus pioglitazone (15 mg o.d. titrated up to 45 mg)
Trial: 15386821
Drug: Metformin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin plus gliclazide (80 mg o.d. titrated up to 320 mg)
Trial: 11870502
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy with sequential subcutaneous IL-2 and IFN-alpha
Trial: 26334096
Drug: Gemcitabine (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (1000 mg/kg2 iv)
Trial: 26334096
Drug: Gemcitabine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine with Pegintron (1 μg/kg sc)
Trial: 26334096
Drug: Gemcitabine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine with Pegintron and p53 SLP vaccine (0.3 mg/peptide, 9 peptides)
Trial: 22643801
Drug: Fast-track rehabilitation
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast-track rehabilitation (Joint Care®) with group therapy, early mobilization (same day as surgery), and 1:1 physiotherapy (2 h/day)
Trial: 17317391
Drug: CVD treatment
RxNorm normalized name: Vibrio cholerae CVD 103-HGR strain live antigen Oral Suspension [Vaxchora]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVD treatment (calcium channel blockers)
Trial: 9362390
Drug: 12 months
RxNorm normalized name: Elecare HMO 0-12 Months
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 months of interferon therapy (IFN), 3-5 MU three times weekly
Trial: 9362390
Drug: 6 months
RxNorm normalized name: leuprolide 45 mg/6 months intramuscular kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 months of observation followed by 6 months of IFN therapy
Trial: 24339936
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: 80 kVp and contrast media of 270 mgI/ml with iterative reconstruction algorithm
Trial: 24339936
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: 120 kVp and contrast media of 320 mgI/ml
Trial: 20523219
Drug: Chronic aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic aspirin therapy
Trial: 20523219
Drug: Chronic antiplatelet
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic antiplatelet therapy (single or dual)
Trial: 1692755
Drug: Caffeine 450
RxNorm normalized name: HYALURONIC ACID 2250 mg in 45 mL / SHEA BUTTER 1800 mg in 45 mL / COLLAGEN, SOLUBLE, FISH SKIN 2250 mg in 45 mL / RETINOL 405 mg in 45 mL / CAFFEINE 450 mg in 45 mL / SIMMONDSIA CHINENSIS (JOJOBA) SEED OIL 450 mg in 45 mL TOPICAL LIQUID [AOAO Retinol Anti-aging Box Set]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 450 mg
Trial: 18458357
Drug: Caffeine 0
RxNorm normalized name: caffeine 0.65 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 0 mg
Trial: 8882988
Drug: Etoposide 200
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide 200 mg/m2/day on days 1‐3 and cisplatin 35 mg/m2/day on days 1‐3 (Phase I)
Trial: 8882988
Drug: Etoposide 200
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide 200 mg/m2/day on days 1‐3 and cisplatin 35 mg/m2/day on days 1‐3 (Phase II)
Trial: 1563057
Drug: Epidural infusions
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural infusions of fentanyl alone
Trial: 3904394
Drug: Metoprolol, 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol, 15 mg intravenously, and 50 mg 4 times a day orally (n = 95)
Trial: 31746629
Drug: Low-dose dopamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dopamine (1-4 µg·kg‐1·min‐1)
Trial: 31746629
Drug: Acute hyperoxia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute hyperoxia + low-dose dopamine
Trial: 29356932
Drug: Standard cold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard cold therapy protocol
Trial: 22362136
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose images
Trial: 1283426
Drug: Fosinopril, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosinopril, a phosphorus-containing ACE inhibitor, administered as a prodrug.
Trial: 1283426
Drug: Standard ACE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard ACE inhibitors that require dosage adjustment due to renal insufficiency.
Trial: 3929609
Drug: 2 gm
RxNorm normalized name: Algiderm 2 gm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 gm solution of cefamandole
Trial: 28135975
Drug: Sorghum group
RxNorm normalized name: Sorghum
DrugBank: Sorghum (DB17914)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorghum group (45g of flaked cereal biscuits daily for 12 weeks)
Trial: 28135975
Drug: White wheat
RxNorm normalized name: WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White wheat group (45g of flaked cereal biscuits daily for 12 weeks)
Trial: 10481420
Drug: 5% dextrose
RxNorm normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% dextrose in Ringer's acetate solution (2 ml)
Trial: 12382386
Drug: 2% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine (2 ml)
Trial: 10481420
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (2 ml) (Control Group)
Trial: 8588396
Drug: L-Dopa 100
RxNorm normalized name: L-DOPA 100 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Dopa 100 to 200 mg
Trial: 1951872
Drug: Chloroquine diphosphate
RxNorm normalized name: CHLOROQUINE DIPHOSPHATE, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine diphosphate (500 mg/week)
Trial: 1951872
Drug: Proguanil hydrochloride
RxNorm normalized name: Proguanil Hydrochloride
DrugBank: Proguanil (DB01131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Proguanil hydrochloride (200 mg/day)
Trial: 7035578
Drug: Polysaccharide-protein complex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polysaccharide-protein complex vaccine
Trial: 15300183
Drug: Oxandrolone (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxandrolone (0.1 mg/kg po bid)
Trial: 2655500
Drug: Therapeutic blood
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic blood patch administered to perpendicular group
Trial: 2655500
Drug: Therapeutic blood
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic blood patch administered to parallel group
Trial: 31201479
Drug: Dronabinol (0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dronabinol (0, 2.5, 5 mg)
Trial: 23040652
Drug: G1: 20mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G1: 20mL L+10mL M
Trial: 23040652
Drug: G3: 15mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G3: 15mL L+15mL M
Trial: 23040652
Drug: G2: 10mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G2: 10mL L+20mL M
Trial: 19888533
Drug: Testosterone treatment
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone treatment (testosterone undecanoate 1,000 mg, intramuscular injections, 5 injections over 40 weeks)
Trial: 9872339
Drug: Intravenous rizatriptan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous rizatriptan (0.5-5 mg)
Trial: 7523132
Drug: Transurethral catheter
RxNorm normalized name: CATHETER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transurethral catheter therapy for 1 hour (Control)
Trial: 7523132
Drug: Transurethral catheter
RxNorm normalized name: CATHETER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transurethral catheter therapy (Control)
Trial: 2802836
Drug: Low-dose recombinant
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose recombinant human growth hormone (GH)
Trial: 30515674
Drug: palbociclib (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: palbociclib (125 mg/day [3 weeks on/1 week off]) plus letrozole (2.5 mg daily)
Trial: 28455600
Drug: Placebo oral
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral preoperatively
Trial: 18359622
Drug: 0.3% dehydroepiandrosterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3% dehydroepiandrosterone (DHEA) applied twice daily for 12 months
Trial: 12730532
Drug: 3-monthly i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-monthly i.v. ibandronate (2 mg) bolus injections
Trial: 12730532
Drug: Oral daily
RxNorm normalized name: Summer's Eve Sheer Floral Daily Cloths
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral daily alfacalcidol (1 micro g)
Trial: 2833090
Drug: Lisinopril alone
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lisinopril alone (group A)
Trial: 2833090
Drug: Lisinopril plus
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lisinopril plus hydrochlorothiazide (group B)
Trial: 26335224
Drug: 37.5 mg
RxNorm normalized name: pemoline 37.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 37.5 mg daily sunitinib therapy
Trial: 22903515
Drug: Vaginal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal misoprostol (400 μg every 6 h)
Trial: 25542295
Drug: Glatiramer acetate
RxNorm normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glatiramer acetate 40 mg/mL three‐times weekly (GA40)
Trial: 24005315
Drug: GHD patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHD patients with 25(OH)D ≥15 ng/ml
Trial: 24005315
Drug: GHD patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHD patients with 25(OH)D <15 ng/ml
Trial: 20961422
Drug: 5.83 mg/mL
RxNorm normalized name: somatropin 5.83 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.83 mg/mL liquid formulation
Trial: 20961422
Drug: 8.0 mg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8.0 mg/mL liquid formulation
Trial: 20961422
Drug: Freeze-dried (FD)
RxNorm normalized name: BLACKBERRY MESOCARP FREEZE DRIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Freeze-dried (FD) formulation
Trial: 10994151
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (amlodipine tablet broken into two halves and encapsulated)
Trial: 10994151
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (amlodipine tablet broken into two halves and ingested as such)
Trial: 29327213
Drug: Adjunctive curcumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive curcumin (500 to 1500 mg/day)
Trial: 29327213
Drug: Adjunctive curcumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive curcumin
Trial: 14655848
Drug: Cognitive‐Behavioral Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive‐Behavioral Therapy (CBT)
Trial: 22374612
Drug: Perfusion group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perfusion group (DXM 2.5 mg/0.5 ml perfused transtympanically for 1 h twice a day for 7 days, total 35.0 mg)
Trial: 22374612
Drug: Drip group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drip group (DXM 2.5 mg/0.5 ml dripped via a ventilation tube once on the first day and twice a day for the remaining 6 days, total 32.5 mg)
Trial: 20595201
Drug: Nutritive solutions
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritive solutions (sucrose and NaCl)
Trial: 20595201
Drug: Harmful solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Harmful solutions (quinine and capsaicin)
Trial: 18341178
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment of 2 NRTI + 1 NNRTI (51%), 3 NRTI (45%), 2 NRTI + 1 PI (4%)
Trial: 12067838
Drug: R-beta-hydroxybutyrate infusion
RxNorm normalized name: beta-citronellol, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-beta-hydroxybutyrate infusion
Trial: 760753
Drug: Urinary excretion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinary excretion of free and conjugated paracetamol
Trial: 30807834
Drug: Antimicrobial photodynamic
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial photodynamic therapy (aPDT) with low intensity laser (InGaAlP) and 0.005% methylene blue photosensitizer
Trial: 25265472
Drug: peginterferon beta‐1a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: peginterferon beta‐1a 125 μg every 2 weeks
Trial: 25265472
Drug: peginterferon beta‐1a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: peginterferon beta‐1a 125 μg every 4 weeks
Trial: 9270664
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIG) 2 g/kg
Trial: 7525790
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (group A) excluding T1 tumours
Trial: 17913583
Drug: No unfractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No unfractionated heparin (no UFH)
Trial: 14609161
Drug: Antibiotic-impregnated shunt
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotic-impregnated shunt (AIS) system
Trial: 22721632
Drug: Isosorbide mononitrate
RxNorm normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide mononitrate (IMN) 2 40-mg tablets
Trial: 29046921
Drug: Pioglitazone (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (45 mg/day)
Trial: 18307460
Drug: Rosiglitazone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone (8 mg/day)
Trial: 9704685
Drug: 1994 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1994 treatment (aspirin, ACE inhibitors, beta-blockers, nitrates, thrombolytic therapy, coronary angiography, PTCA, CABG)
Trial: 8046740
Drug: Pentamidine therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentamidine therapy
Trial: 19794987
Drug: Antihistamine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihistamine (2 mL, 45.5 mg pheniramine maleate)
Trial: 25199696
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (2 mL)
Trial: 1704245
Drug: Self-help materials
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-help materials (audiotape and booklet) in addition to current treatment
Trial: 1704245
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (current treatment only)
Trial: 7286031
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of diacetolol 800 mg
Trial: 26773246
Drug: Carbetocin (100mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbetocin (100mcg intravenous bolus)
Trial: 26773246
Drug: Oxytocin (10IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxytocin (10IU intravenous bolus)
Trial: 25157951
Drug: Extended-release oxycodone/acetaminophen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release oxycodone/acetaminophen (ER OC/APAP) 15/650 mg total dose, two tablets every 12 hours for ≤ 14 days
Trial: 25157951
Drug: Extended-release oxycodone/acetaminophen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release oxycodone/acetaminophen (ER OC/APAP)
Trial: 21811833
Drug: Pazopanib 400
RxNorm normalized name: PAZOPanib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib 400 mg crushed tablet
Trial: 21811833
Drug: Pazopanib 400
RxNorm normalized name: PAZOPanib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib 400 mg oral suspension
Trial: 21811833
Drug: Whole tablet
RxNorm normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole tablet administration
Trial: 17467954
Drug: Prolactin-sparing anti-psychotics
RxNorm normalized name: prolactin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolactin-sparing anti-psychotics (e.g., olanzapine) with specific interventions (n=8)
Trial: 17540667
Drug: Aprepitant 40
RxNorm normalized name: aprepitant 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprepitant 40 mg
Trial: 12482109
Drug: Pulsed estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed estrogen therapy (Aerodiol)
Trial: 2676648
Drug: Salsalate (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salsalate (1.5 g twice daily)
Trial: 2676648
Drug: Piroxicam (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam (20 mg after evening meal)
Trial: 23741991
Drug: Fosamprenavir/ritonavir 1400/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosamprenavir/ritonavir 1400/100 mg with abacavir/lamivudine 600 mg/300 mg
Trial: 8387904
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 500 mg MK-886
Trial: 8387904
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of 250 mg MK-886 every 8 hours
Trial: 2873133
Drug: thioridazine 800
RxNorm normalized name: Thioridazine
DrugBank: Thioridazine (DB00679)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: thioridazine 800 mg/day
Trial: 29382036
Drug: BoNT/A injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BoNT/A injections into four glands
Trial: 29382036
Drug: BoNT/A injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BoNT/A injections into three glands
Trial: 29382036
Drug: BoNT/A injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BoNT/A injections into two glands
Trial: 29382036
Drug: BoNT/A injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BoNT/A injections (overall)
Trial: 24656867
Drug: Multimodal manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal manual treatment approach including analyzing treadmill with feedback, isokinetic dynamometric muscle strengthening, and balance retraining on dynamic balance platform
Trial: 18443125
Drug: AMD3100 therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AMD3100 therapy for 10 days
Trial: 23820927
Drug: Modafinil (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil (100 mg)
Trial: 9811522
Drug: Whole cell
RxNorm normalized name: pertussis, whole cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole cell pertussis vaccine (DPT)
Trial: 9811522
Drug: Acellular vaccines
RxNorm normalized name: PERTUSSIS VACCINE,ACELLULAR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acellular vaccines (DTaP‐12.5 and DTaP‐25)
Trial: 3055672
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg decaris weekly (150 mg for 2 successive days) for 15 months (group 3)